Raymond James Initiates Coverage On Quince Therapeutics with Outperform Rating, Announces Price Target of $72
Quince Therapeutics, Inc. (QNCX) Discusses LAM-001 Clinical Progress in Pulmonary Hypertension and Bronchiolitis Obliterans Syndrome Transcript
This Ares Management Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Rodman & Renshaw Initiates Coverage On Quince Therapeutics with Buy Rating, Announces Price Target of $70
Quince Therapeutics, Inc. (QNCX) OrphAI Therapeutics Inc - M&A Call - Slideshow (NASDAQ:QNCX) 2026-05-18